Cargando…
Marketing Authorization Applications Made to the European Medicines Agency in 2018–2019: What was the Contribution of Real‐World Evidence?
Information derived from routinely collected real‐world data has for a long time been used to support regulatory decision making on the safety of drugs and has more recently been used to support marketing authorization submissions to regulators. There is a lack of detailed information on the use and...
Autores principales: | Flynn, Robert, Plueschke, Kelly, Quinten, Chantal, Strassmann, Valerie, Duijnhoven, Ruben G., Gordillo‐Marañon, Maria, Rueckbeil, Marcia, Cohet, Catherine, Kurz, Xavier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299056/ https://www.ncbi.nlm.nih.gov/pubmed/34689339 http://dx.doi.org/10.1002/cpt.2461 |
Ejemplares similares
-
Contribution of Real‐World Evidence in European Medicines Agency's Regulatory Decision Making
por: Bakker, Elisabeth, et al.
Publicado: (2022) -
Collection of Data on Adverse Events Related to Medicinal Products: A Survey Among Registries in the ENCePP Resources Database
por: Plueschke, Kelly, et al.
Publicado: (2022) -
Evaluation of Companion Diagnostics in Scientific Advice and Drug Marketing Authorization Applications by the European Medicines Agency
por: Maliepaard, Marc, et al.
Publicado: (2022) -
Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency
por: Elsäßer, Amelie, et al.
Publicado: (2014) -
Pharmacogenetic‐Pharmacokinetic Interactions in Drug Marketing Authorization Applications via the European Medicines Agency Between 2014 and 2017
por: Maliepaard, Marc, et al.
Publicado: (2020)